“We will also showcase a plethora of original data on cutting-edge research that improves patient care through the use of innovative cancer therapy for tomorrow," said Phil Talamo, vice president, independent medical education and operations at PER.
Plainsboro, NJ (PRWEB) August 31, 2015
Physicians’ Education Resource®, LLC (PER®), the accreditor and provider of the CME-certified annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® meeting, is seeking abstract submissions for its 33rd annual conference to be held Nov. 4 – 6 in New York City. The annual legacy meeting uses a variety of formats to educate all disciplines of cancer care on state-of-the-art treatments and management strategies.
This year’s symposium will continue to focus on “innovative cancer therapy for tomorrow,” including the most relevant advances in cancer care through most cancer types. PER invites abstract submissions on all cancer-related subjects, including hematologic malignancies, gastrointestinal cancers, gynecologic malignancies, head and neck cancers, immunotherapies, melanoma and other cutaneous malignancies, lung cancers, genitourinary malignancies and more. It also welcomes submissions on management issues such as survivorship, precision medicine, clinical trials, healthcare reform and value-based care.
“The symposium agenda this year will continue to feature many reputable oncology experts from around the world,” said Phil Talamo, vice president, independent medical education and operations at PER. “With the accepted abstracts, we will also showcase a plethora of original data on cutting-edge research that improves patient care through the use of innovative cancer therapy for tomorrow. As the largest CME-certified multi-tumor meeting on the East Coast, we are excited to add this new feature to our conference as we know it will enhance the learning of our participants.”
Abstracts and posters will be available for viewing, both live at the 2015 Chemotherapy Foundation Symposium and on the website during and after the conference. The submission deadline is Friday, Sept. 25, 2015, at 11:59 a.m. EST. Abstracts should comprise a short description of the relevant work, defining goals and results. For details on how to submit abstracts and posters, go to http://www.gotoper.com.
“Expert pioneers in virtually every tumor subspecialty will provide expert insight on new developments in cancer therapeutics during this symposium,” added Talamo. “Our attendees will participate in sessions to learn about new compounds, novel approaches to diagnosis and treatment with currently available agents, ongoing clinical trials and emerging developments to help them in their daily practice. Now, we will even have a forum to showcase their research. It is truly a one-of-a-kind meeting.”
Symposium attendees can earn a maximum of 23 American Medical Association PRA Category 1 continuing education credits. Topics on the agenda include Novel Immuno-Oncology Strategies for the Treatment of Solid Tumor, The “Next Generation” of Anti-Cancer Agents, Addressing Resistance in the Era of Personalized Cancer Care, The Changing Landscape in Ovarian Cancer and Looking Ahead Towards the Future of Treating Soft-Tissue Sarcoma. There will be five hours of hematology content and three hours each of content on lung and gastric cancers.
PER Events, LLC, an affiliate of accredited medical education provider Physicians’ Education Resource, (PER), acquired the Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow last May. The acquisition combined the legacy of one of the largest oncology/hematology conferences with PER’s expanding portfolio of educational meetings to keep oncologists and their practices up-to-date on the latest advances in cancer treatment. It also deepened the commitment of Michael J. Hennessy Associates, Inc. (MJH), corporate parent of PER, to advancing cancer care through a broad range of educational, research and communications services for the oncology community.
PER is dedicated to advancing cancer care through professional education. Accredited by the Accreditation Council for Continuing Medical Education, PER is the “go-to” source for continuing medical education (CME) in oncology and hematology. PER provides high-quality, evidence-based CME-certified activities that translate the science of oncology into the art of patient care by featuring leading national and international faculty that focus on practice-changing advances to help the busy oncologist to stay up-to-date with cutting-edge oncology knowledge and treatments. PER serves the oncology healthcare community, including physicians, nurses, nurse practitioners, physician assistants and pharmacists. PER is part of the Plainsboro, N.J.-based Michael J. Hennessy Associates, Inc. (MJH), family of businesses. Learn more at http://www.gotoper.com and http://www.mjhassoc.com.
About the Chemotherapy Foundation
The Chemotherapy Foundation is a 501(c)(3) tax-exempt nonprofit organization founded in 1968 and dedicated to the control, cure and prevention of cancer through innovative medical therapies. The Foundation provides crucial seed money to gifted researchers at institutions in the greater New York City area to start groundbreaking work designed to facilitate breakthrough science. By combining aggressive research with professional education and implementation, the Foundation’s programs are widely recognized in oncology for their significant contributions to improved patient care, disease management and survival. Learn more at http://chemotherapyfoundation.com/.
Media Contacts for PER:
Becky Taylor, 609-240-6886, becky(at)btaylorpa(dot)com
Robert Walker, 609-378-3730, rwalker(at)gotoper(dot)com